BERWYN, PA — Nordic Pharma, Inc. said it recently began shipping cannulas with its LACRIFILL Canalicular Gel syringes as it expands its offering following feedback from physicians using the dry eye treatment.
The company said the change comes as more than 100,000 patients in the United States have been treated with LACRIFILL in less than two years since its launch.
LACRIFILL is a single-use syringe containing a cross-linked hyaluronic acid gel designed to temporarily block tear drainage by occluding the canalicular system, helping manage dry eye symptoms.
The product is administered using a cannula inserted into the punctum, allowing the gel to flow into the lacrimal sac.
Each package contains 10 pre-filled syringes and now includes 10 cannulas, the company said.
Nordic Pharma launched LACRIFILL in the United States in May 2024 after receiving clearance from the Food and Drug Administration.
The company said the decision to include cannulas followed physician feedback and has been well received.
“As physicians, we must take an active role in controlling our patients’ ocular surface health,” said Dr. Eric Donnenfeld of OCLI Vision and NYU Langone Health, who described the product as an alternative to traditional punctal plugs.
Dr. Mile Brujic of Premier Vision Group said the treatment has been used in both routine dry eye care and surgical patient management, citing improvements in patient comfort and visual outcomes.
Jai Parekh, chief commercial officer of Eye Care US, said the product’s adoption reflects growing focus on interventional approaches to dry eye disease.
Dry eye disease affects about 6.8% of U.S. adults, according to the company.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.